Objective. To determine the pattern of demyelinating disorders (DDs) occurring during anti-TNF-a therapy.
Introduction
The development of anti-TNF-a therapy is probably one of the most significant achievements in the treatment of inflammatory rheumatic diseases. However, the benefitrisk ratio of these therapies has to be considered. These treatments are associated with various and potentially severe side effects. Apart from the well-known and recognized infectious complications, rare cases of neuroinflammatory demyelinating disorders (DDs), such as multiple sclerosis (MS), myelitis and optic neuritis, have been reported with anti-TNF-a [1] . Moreover, anti-TNF-a treatment of patients with MS has been reported to cause clinical worsening and/or increased inflammatory activity markers, as evaluated by brain MRI and cerebrospinal fluid (CSF) IgG index [2, 3] . Current guidelines now recommend avoiding their use in patients with a personal or family history of central DD. In addition, cases of demyelinating neuropathies such as GuillainBarré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy have been reported in patients treated with anti-TNF-a [47] .
Given the growing use of these agents in clinical practice, it is important to critically consider the possible association between drug and DD before assuming causality. This prompted us to collect and analyse cases of DDs occurring in anti-TNF-a-treated patients.
Patients and methods

Selection of patients
Between June 2005 and April 2008, the 1800 French rheumatology and internal medicine physicians registered on the Club Rhumatismes et Inflammation (a section of the French Society of Rheumatology) website (http://www. CRI-net.com) were contacted by four successive electronic newsletters to collect observations of DD affecting either the CNS or the peripheral nervous system (PNS) occurring in patients treated with anti-TNF-a for any inflammatory disorder. The cases were considered only if the DD appeared after anti-TNF-a initiation. CNS white matter lesions were not considered if they were not associated with clinical symptoms. Patients with neurological symptoms not related to DD were excluded.
Data collection
Data were collected using a standardized form, including demographic and clinical data on the underlying disease and the neurological complication.
For all cases, imputability score was calculated using the 10-item Naranjo adverse drug reaction probability scale [8] . Adverse drug reaction was considered as definite (59), probable (58), possible (14) or doubtful (40). All medical charts were searched for the presence of revised 2005 McDonalds MS criteria in case of CNS involvement [9] , or for the presence of consensus CIDP diagnosis criteria in case of PNS involvement [10, 11] .
Statistical analysis
Values are reported as number and/or percentage for categorical variables and median (range) for continuous variables. Characteristics of patients with central and peripheral DD were compared. Qualitative variables were compared using a chi-square test or, when appropriate, Fisher's exact test, and quantitative variables using MannWhitney test. For all statistical analyses, P 4 0.05 was considered significant. Statistical analyses were conducted using SAS software, version 9.1 (SAS Institute Inc., Cary, NC, USA).
Results
Patient and treatment characteristics
During the study period, 38 patient files were retrieved. Five were excluded because neurological symptoms were not related to demyelinating inflammatory disorder: two patients with meningo-radiculitis, one patient with VogtKoyanagiHarada, one with seizure and one with human herspesvirus 6-related facial nerve palsy (supplementary Fig. S1 , available as supplementary data at Rheumatology Online).
Characteristics of the 33 patients who developed DD during anti-TNF-a therapy are described in Table 1 . Two have been previously described [12] . None had familial or personal past history of DD. The median follow-up was 19.7 (3.466.4) months from neurological symptom onset.
Anti-TNF-a was infliximab in 15 (45.4%) patients, etanercept in 12 (36.4%) and adalimumab in 6 (18.2%). A DMARD was co-prescribed in 16 (48.5%) patients, MTX in 10, SSZ in 3 (with HCQ in 1), LEF in 2 and AZA in 1. Seven patients had previously received another anti-TNF-a treatment, without experiencing neurological symptoms in six.
Pattern of CNS involvement
Of 22 patients with CNS involvement ( Fig. S1 , available as supplementary data at Rheumatology Online). CSF analysis was normal in 6 patients, revealed raised protein level in 4, immunoglobulin oligoclonal bands in 11 and/or pleiocytosis in 4. MRI showed multiple white matter lesions in all but two patients (with isolated optic neuritis). Evoked potential testing, performed in 10 patients, was abnormal in 6: abnormal somatosensory potential in 3, abnormal visual potential in 2 and abnormal motor, somato-sensory and visual potential in 1. Anti-TNF-a treatment was discontinued in all patients. Fifteen patients received glucocorticoids for neurological involvement: methylprednisone pulses in 13 and high-dose prednisone in 2. Neurological symptoms completely regressed in 12 patients, partly in 8 and remained stable in 2. Demyelination during anti-TNF-a therapy criteria [9] . All relapsed from encephalic involvement with new neurological symptoms and new MRI lesions. Three patients received IFN-b with efficacy, but one patient further relapsed despite IFN.
Pattern of PNS involvement
Eleven patients had PNS involvement (Table 2) : CIDP in nine and GuillainBarré syndrome in two (supplementary Fig. S1 , available as supplementary data at Rheumatology Online). One patient treated with infliximab had a history of similar neurological symptoms with etanercept 2 years before that regressed after discontinuation. CSF analysis, performed in 10 patients, revealed raised protein in 9 patients. In the last patient, CSF analysis was normal but nerve conduction study (NCS) revealed typical features of CIDP, and anti-GD1b antibodies were found in sera. In the nine patients with CIDP, NCS showed typical features of CIDP in eight [10, 11] and was suggestive of DD in one. NCS abnormalities were conduction block or temporal dispersion in six, reduced motor nerve conduction velocity in six, prolonged F wave latency in three and distal prolonged latency in three. Nerve biopsies, performed in two patients, showed histopathological findings of a demyelination/remyelination process in both cases. Antiganglioside antibodies were tested in four patients and were found to be present in three. Anti-TNF-a was discontinued in 10 patients. Eight patients received i.v. immunoglobulins (IVIg); five received a single course and three received several courses. Regression of neurological symptoms was observed in all: two completely recovered and six partly improved. Two patients did not receive specific treatment. Neurological symptoms initially remained stable in both, but improved in one when rituximab was initiated for the underlying disease 3 years later. One patient persisted on anti-TNF-a; neurological symptoms remained stable. Two patients relapsed after IVIg discontinuation, one 12 months later without anti-TNF-a and one 3 months after IVIg discontinuation when adalimumab was introduced. This last patient further improved with discontinuation of adalimumab and reintroduction of IVIg.
Imputability score
According to the Naranjo adverse drug reaction probability scale [8] , the probability that anti-TNF-a induced the adverse drug reaction was considered as probable in 31 patients (scores ranging from 6 to 7) and definite in 2 (scores of 9).
Outcome of underlying disease
After anti-TNF-a discontinuation, 23 (71.8%) patients experienced a flare of their underlying rheumatic disorder: RA (n = 11), AS (n = 8), PsA (n = 3) and JIA (n = 1). Among the RA patients, four patients remained on MTX alone and five patients received anakinra, which was discontinued for inefficacy in all. One patient received adalimumab but relapsed from CIDP. Six patients further received rituximab. In AS patients, a DMARD was introduced in five patients [AZA (n = 3), MTX (n = 1), MMF (n = 1)], with moderate or no efficacy. Etanercept was maintained in one and introduced in one other patient without sufficient follow-up to evaluate neurological outcome. Results are presented as median (minimummaximum) or n (%). 
Discussion
We report 33 cases of DDs occurring during anti-TNF-a therapy. After long-term follow-up, neurological symptoms regressed in most of the cases. But in a minority of patients, neurological disorder evolved despite anti-TNF-a discontinuation; 22% of the patients with CNS involvement developed MS. This survey is the biggest study addressing the issue of DD that has collected CNS and PNS complications using the same methodology.
To examine the association between anti-TNF-a and DD, we calculated the imputability score. The score was relatively high for all patients and suggested causality in two patients with positive rechallenge. Complete resolution following discontinuation of anti-TNF-a in some patients also suggested a link between the drug and the DD, while neurological symptoms persisted after drug discontinuation in other patients. Nevertheless, in drug-induced cutaneous reactions, where complete regression is usual, the outcome of neurological complications is more difficult to appraise because anatomical lesions may induce irreversible symptoms related to damage rather than a persistent active process.
In France, the estimated prevalence of MS is more than 50/100 000 inhabitants and annual incidence is 47/ 100 000 inhabitants [13] . The prevalence of CIDP is much lower: 1.21.9/100 000 inhabitants with an annual incidence of 0.15/100 000 inhabitants [14] . In our study, CNS involvement occurred twice as often as PNS involvement. Even if some cases have been missed, because we used the same methodology to collect both complications, it is improbable that PNS involvement was more systematically declared than CNS involvement. Therefore it is likely that PNS demyelination was more frequent than expected compared with CNS involvement. Interestingly, in contrast to opportunistic infections, the rate of DD does not seem to be different between the soluble receptor and the monoclonal antibodies.
It has been previously estimated, from the RATIO study [15] , that about 57 700 patient-years were treated with anti-TNF-a in France between 2004 and 2006, resulting in approximately 20 000 patients treated each year. However, our methodology prevents us from providing any incidence rates because the present study was not conducted during the same period, and also we could not assume that we exhaustively captured all the cases of neurological DD during the study period.
Although in RA the primary autoimmune condition may be a contributing factor to the development of DDs [16] , other inflammatory rheumatic disorders, particularly SpAs, are not classically associated with immune neurological disorders. Since almost half of our patients had SpAs, it is unlikely that the underlying rheumatic disease was a major contributor to the development of the neurological disorder.
We are aware that the scientific value of a retrospective analysis is limited compared with a prospective study. However, because of the rarity of these complications, no single prospective study can address this question and only isolated case reports are available [17] .
In addition, the possible link between anti-TNF-a therapy and demyelination is reinforced by the observed worsening of demyelinating features in patients with MS treated with anti-TNF-a [2, 3] .
Even if the imputability of anti-TNF-a in induction of DD remains unclear, in some cases, the chronology of clinical events is suggestive. Nevertheless, DD might persist despite discontinuation, suggesting that anti-TNF-a could trigger the demyelinating process, which further progresses independently. Most patients required specific treatment of neurological DD with a variable neurological outcome, indicating that in addition to anti-TNF-a discontinuation, the management of these patients should be similar to that of patients with idiopathic DD.
Rheumatology key messages
. Central and peripheral neurological demyelinating complications can occur during anti-TNF therapy. . Peripheral demyelinating complications occurring during anti-TNF therapy could be more frequent than those expected from central ones. . About a quarter of patients with CNS involvement developed MS despite discontinuing anti-TNF.
